Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Core Insights - Obagi Medical has selected Schweiger Dermatology as a key partner for its Aesthetics Leadership with the Hyaluronic Acid (ALOHA) Program, emphasizing clinical excellence and rapid access to care [1] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare and aesthetic solutions, with over 35 years of experience in the industry [7] - Schweiger Dermatology is a prominent national dermatology practice that offers a range of services including medical, cosmetic, and surgical dermatology, focusing on high-quality, personalized care [8] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [9] Partnership Details - The partnership will generate real-world data to translate clinical safety and efficacy from FDA pivotal trials into everyday practice [2] - The ALOHA Program includes a Phase 4 clinical study and a real-world evaluation program to enhance patient satisfaction and provider-patient relationships [3] - Initial program activities are expected to commence in early 2026, with findings to be presented at internal leadership meetings and key industry conferences [4] Product Information - Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, aiming for natural-looking results and high performance [5]